TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05203965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056)
Description: Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056)
Description: Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056)
Description: Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056)
Description: Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
Study: NCT05465720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: falls-prevention programs
Description: Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: falls-prevention programs
Description: Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: falls-prevention programs
Description: Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
Study: NCT05683184

Intervention type: DRUG
Group type: OTHER
Intervention: [11C]OMAR
Description: For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: [11C]OMAR
Description: For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
Study: NCT06738030

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Auditory training
Description: An at-home auditory training program that adaptively and interactively trains the listener in degraded speech, cognitive skills, and communication strategies
Study: NCT06740097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspirate tissue monitoring
Description: This multicenter controlled clinical trial investigates the clinical performance and outcomes from using an aspirate tissue monitor (ATM, Marginum Ltd HIVEN™) that detects cancerous tissue from the suction waste during the surgical treatment of suspected high-grade gliomas. The ATM provides near real-time audible feedback to the surgeon when tumor-related fluorescence is detected in the aspirated tissues. The trial investigates if the use of ATM to detect 5-ALA induced fluorescence contributes to faster tumor removal, less blood loss, less unintended residual tumor, less morbidity, longer survival and the frequency of local reoperations. The cases are compared with controls (n=50) from applicable local clinical site registers (matched controls). The cases are operated with the help of aspirate tissue monitoring and the controls without. Other preferred adjunct techniques are used in both groups.
Study: NCT06361407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illusion task
Description: The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
Study: NCT06055686

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrical Epidural Stimulation Test
Description: Electrical stimulation test measures sensory/motor responses
Study: NCT06064318

Intervention type: PROCEDURE
Intervention: Revision
Description: Any type of knee revision, excluding knee arthrodesis and femur amputation
Study: NCT04431427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary drainage with PC-SEMS
Description: partially covered metallic biliary stent insertion during ERCP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary drainage with U-SEMS
Description: Uncovered metallic biliary stent insertion during ERCP
Study: NCT05176210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS1
Description: PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as a 120 mg tablet.
Study: NCT05734937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastric assessment of gastric volume
Description: ultrasound assessment of gastric volume is going to bel evaluted in the Preoperative and postoperative period while the patients lay in right lateral decubitus position.
Study: NCT05216263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study: NCT06150209

Intervention type: DEVICE
Group type: OTHER
Intervention: Vendaje
Description: Dehydrated Human Amniotic Membrane
Study: NCT06264453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH001
Description: topical applications of KH001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH001
Description: topical applications of KH001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical applications of Water for Injection
Study: NCT05300529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Exercises
Description: The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional Rehabilitation exercises
Description: The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
Study: NCT05677945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3Mixtatin paste: Simvastatin mixed with modified triple antibiotic
Description: * Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3Mix: Modified triple antibiotic mix in propylene glycol
Description: * Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement.
Study: NCT06656234

Intervention type: DRUG
Intervention: Glofitamab
Description: Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Obinutuzumab
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
Study: NCT05627193

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teleclinic
Description: Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Clinic
Description: Patients will have to travel to come physically to hospital to meet the operating surgeon.
Study: NCT05811195

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Semiconductor, Duo
Description: Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gemini laser
Description: Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
Study: NCT05932030

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Submission of a survey to solid organ transplant patients and health professionals working in transplantation to assess their knowledge and perception of the use of artificial intelligence in transplantation
Study: NCT05082155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
Study: NCT06570291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal progenitor cells
Description: Allogenic adipose tissue-derived mesenchymal progenitor cells administrated for intra- articular use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate Injection
Description: Sodium Hyaluronate administrated for intra-articular use
Study: NCT05340907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Device
Description: A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
Study: NCT06138873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation-index guided ventricular tachycardia ablation
Description: As described in arms descriptions
Study: NCT06124677

Intervention type: DRUG
Intervention: Faricimab
Description: The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
Study: NCT06740097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescence-guided surgery
Description: Resection utilizing conventional visual fluorescence-guided surgery.
Study: NCT05428917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple task
Description: The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform flexion / extension movements of the fingers of the left hand at 0.5 Hz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: complex task
Description: The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform an exercise based on the nine hole peg test
Study: NCT06739577

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG))
Description: To evaluate walking abilities, participants performed the Timed-Up \& Go (TUG) f our times (practice trial, normal, slow and fast speed). Patient's performances are videorecorded with an Intel RealSense depth camera D435i to capture their movements, and manual time recording of time taken (in seconds) and number of steps are carried out by the experimenters.~Complementary to manual experimenter recording, a 2D human pose estimation method (OpenTUG) is applied to automatically extract the time and the number of steps taken by the participant during the TUG task.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG))
Description: To evaluate walking abilities, participants performed the Timed-Up \& Go (TUG) f our times (practice trial, normal, slow and fast speed). Patient's performances are videorecorded with an Intel RealSense depth camera D435i to capture their movements, and manual time recording of time taken (in seconds) and number of steps are carried out by the experimenters.~Complementary to manual experimenter recording, a 2D human pose estimation method (OpenTUG) is applied to automatically extract the time and the number of steps taken by the participant during the TUG task.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.
Description: Neuropsychological evaluation assess attention (Test for Attentional Performance -TAP-) and quality-of-life (DHI, HADS, and NVI).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.
Description: Neuropsychological evaluation assess attention (Test for Attentional Performance -TAP-) and quality-of-life (DHI, HADS, and NVI).
Study: NCT05319054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral NeuroModulation
Description: Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-Anal Irrigation
Description: Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised Conservative Management
Description: Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised Conservative Management
Description: Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised Conservative Management
Description: Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
Study: NCT06737068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum (8-10mmHg) with AirSeal device
Description: Elective robot assisted hiatal hernia repair with low pressure pneumoperitoneum (8-10mmHg) with AirSeal device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device
Description: Elective robot assisted hiatal hernia repair with standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device
Study: NCT06740630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine_Lot 1
Description: Investigational varicella vaccine of Lot 1 administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine_Lot 2
Description: Investigational varicella vaccine of Lot 2 administered subcutaneously.
Study: NCT06299280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task training
Description: students will be given additional cognitive tasks while exercising in physical education class

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single task training
Description: students will exercise in physical education class, without additional cognitive tasks
Study: NCT06740630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine_Lot 3
Description: Investigational varicella vaccine of Lot 3 administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed varicella vaccine_Lot 1
Description: Marketed varicella vaccine of Lot 1 administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed varicella vaccine_Lot 2
Description: Marketed varicella vaccine of Lot 2 administered subcutaneously.